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Abstract 
The immune checkpoint protein programmed 
death ligand-1 (PD-L1) is expressed in different 
types of cancer and is a potential prognostic 
factor as well as therapeutic target. 
This study evaluated PD-L1 expression in the 
neoplastic progression of vulvar epithelia with 
respect to the pattern of infiltration in FIGO 
stages I keratinizing squamous cell carcinomas 
(SCC). Normal squamous vulvar epithelia 
(n=20), usual type vulvar intraepithelial 
neoplasia (uVIN, n=23), differentiated VIN 
(dVIN, n=21) and FIGO stage I SCC (n=35) 
were immunostained for PD-L1. In SCC a 
cohesive growth with well-delineated borders 
was considered as pushing, dissociative growth 
in small groups or single cells was defined as 
diffuse pattern of infiltration. Immunostaining 
was done with a monoclonal anti PD-L1 
antibody (clone SP263, Ventana) and scored to 
determine up-regulation and overexpression 
(score 0/1+, 0-5% immunoreactive cells; score 
2+, >5 to 50% immunoreactive cells; score 3+, 
>50% immunoreactive cells). PD-L1 
immunoexpression was comparable in normal 
epithelia and VINs (score 0/1+, n=59; score 2+, 
n=5, in VINs only; score 3+, n=0), was 
significantly increased (P<0.0001) in SCC (score 
0/1+, n=13; score 2+, n=16; score 3+, n=6), and 
was related to a diffuse pattern of infiltration 
(P<0.0001). Staining was accentuated at the 
invasive margins of SCC frequently. PD-L1 
expression is up-regulated in the neoplastic cells 
of vulvar low stage SCC, related to the 
development of an invasive phenotype reflecting 
the initiation of cancer immunoediting, and to an 
aggressive diffuse type of stromal invasion. 
1Department of Pathology, Landesklinikum 
Baden-Moedling, Baden, Austria 
Introduction 
Invasive squamous cell carcinoma 
(SCC) is the most common type of all 
invasive vulvar cancers. High grade 
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vulvar intraepithelial neoplasias (VIN) 
are precancerous changes, defined as 
proliferative intraepithelial squamous 
lesions which display abnormal growth.  
Basaloid and warty (condylomatous) or 
usual subtypes of VIN (uVIN) are 
associated with relatively younger 
women, and evidence of human 
papillomavirus (HPV) nucleic acids. The 
differentiated subtype of VIN (dVIN) is 
associated with relatively older women 
and develops independently of HPV. 
The morphologic and etiologic 
heterogeneity of VIN is consistent with a 
dual pathogenesis of vulvar squamous 
cell carcinomas. Warty or basaloid 
carcinomas are related to the presence 
of HPV, genital warts, uVIN, and occur 
in younger women. In contrast, 
keratinizing SCC is frequently found in 
women older than 55 years, is usually 
unrelated to HPV infection, but may be 
associated with dVIN and lichen 
sclerosus. This type of SCC accounts 
for 65% of vulvar invasive SCC and 
marks another pathway in the 
development of these tumors.1  
The recent interest in therapeutic 
immune checkpoint inhibition targeting 
programmed cell-death receptor (PD-1) 
or its ligand programmed death ligand 1 
(PD-L1) has resulted in evidence for 
clinicopathologic relevance of these 
factors in different cancer types (e.g. 
non-small cell lung cancer, melanoma, 
lymphomas, etc.).2-5 PD-L1 is not 
expressed or expressed in low levels in 
most normal cells, but frequently up-
regulated in tumor cells, stromal cells 
including immune cells, or both, and is 
amenable to immunohistochemical 
evaluation.2,3 PD-L1 expression has 
been studied in vulvar SCC, too.6--11 
However, the pattern of invasion is well 
known to be associated with aggressive 
clinical behaviour in SCC of the vulva 12, 
and has not been investigated for PD-L1 
expression. This study hypothesized 
that an aggressive pattern of invasion 
may be related with PD-L1 
overexpression in vulvar SCC. Thus, 
cohorts of early stage vulvar HPV-
independent SCC and dVIN as well as 
uVIN were analysed to study and 
compare the epithelial PD-L1 
immunoexpression in intraepithelial as 
well as early invasive neoplastic tissues.  
Materials and Methods 
Tissue specimens 
A total of 99 diagnostic vulvar tissues 
originating from 64 preoperatively 
untreated patients were included in this 
retrospective study. Each patient 
contributed one tissue block only. This 
study was carried out in accordance 
with local ethical guidelines and the 
approval of the local ethics committee of 
Lower Austria (GS1-EK-4/584-2019). 
The specimens consisted of vulvar 
biopsies, local excisions as well as 
partial and total vulvectomies collected 
from the files of the author´s institution 
and were obtained between 1998 and 
2014. Cases included in this study were 
largely retrieved from a previous series 
used for studies on vulvar squamous 
tissues.13,14 Inclusion criteria into the 
recent study cohort were availability of 
tissue blocks with sufficient tissue for 
recutting and immunohistochemical 
stains which were defined as a diameter 
of diagnostic tissue of at least 1cm as 
well as quality of the tissue remaining 
after previous studies. Tissue blocks not 
meeting these criteria were excluded 
and replaced by more recent cases of 
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appropriate size and quality up to 2014. 
In ten cases of SCC a lymph node 
dissection was performed, with no 
evidence of metastatic deposits. If 
present in the studied slides, normal 
epithelia as well as lower grade lesions 
adjacent to higher grade changes were 
evaluated, too. The histological 
diagnoses were as follows: normal 
epithelia (NE, n=20), uVIN (n=23), dVIN 
(n=21), SCC (n=35). Six cases of d-VIN 
were isolated; the others d-VIN cases 
were associated with SCC. No uVIN 
was noted in the cases of SCC included 
in this study. The specimens were fixed 
in formalin and embedded in paraffin. 
Formalin fixation did not exceed 24h. In 
each case, all original hematoxylin-and-
eosin-stained sections as well as the 
clinical histories were reviewed, and a 
representative tissue block was chosen 
for immunohistochemical staining. 
Information regarding follow-up of 
patients with SCC was retrieved from 
the pathological files of the author´s 
institution as well as by contacting the 
attending gynecologists. Three of the 
patients with SCC experienced recurrent 
disease one to 10 years after the 
primary diagnosis.  Due to the small 
number of these cases a further 
statistical evaluation was not done. 
 
 
Figure 1. A case of dVIN showing a widened epithelium, with acanthosis, basal 
atypia and abnormal maturation of keratinocytes with abundant eosinophilic 
cytoplasm and abnormal nuclei adjacent to a squamous cell carcinoma with a 
diffuse pattern of infiltration (arrow). Rete ridges are somewhat elongated, broad 
and confluent. (H&E, x100). 
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The classification of VIN as well as the 
staging of the SCC was performed as 
described previously.1,15 All SCC 
belonged to the keratinizing subtype, 
were immunonegative for p16 and 
diffusely positive for p53 in a strong 
nuclear staining pattern. Applying the 
FIGO staging, all cases of SCC were 
staged as FIGO I. The mean age of 
patients with SCC was 70.3 (range: 46-
90) years. The uVIN (mean age: 43.4 
years, range: 28-62 years) lesions 
covered by this study were p16 positive 
in a diffuse block-like pattern on 
immunohistochemistry.1 DVIN (mean 
age: 67.8 years, range: 46-90 years) 
was recognized by defined criteria such 
as basal atypia and abnormal 
maturation of keratinocytes with large 
abundant eosinophilic cytoplasm, 
abnormal nuclei, and prominent nucleoli 
(Figure 1).1  
 
 
Figure 2. Same case as shown in Fig.1. P53 immunostaining is seen in >90% of 
the basal/parabasal two to three cell layers. At the left there is normal squamous 
epithelium with occasional basal cell staining, corresponding to a wild type of 
immunoreactivity. (p53, x100). 
The rete ridges were elongated and 
branching frequently, with occasional 
keratin pearls and acanthosis. In the 
superficial layers, atypia was minimal 
and maturation was maintained. These 
lesions have been shown p53 reactive, 
there was no diagnostic staining for p16. 
P53 reactivity in dVIN was seen in the 
basal/parabasal two to three cell layers 
in a mutant phenotype represented by 
strong nuclear staining.16,17 (Figure 2) 
The original tissue blocks and slides 
(hematoxylin-eosin/H&E as well 
immunohistochemical stains) were 
reviewed by the author. Epithelial 
lesions not matching the above-
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mentioned criteria (lichen sclerosus, 
lichen simplex chronicus, 
pseudoepitheliomatous hyperplasias, 
acanthotic lesions with altered 
differentiation, etc.) were not included in 
this study. 
Immunohistochemistry 
The same paraffin-embedded tissues as 
those used for the original H&E stained 
sections were used for 
immunohistochemistry. They were cut at 
3µm. Subsequently, the sections were 
deparaffinized in xylene and rehydrated 
via graded ethanol. A standard 
immunohistochemical technique was 
performed using a Ventana BenchMark 
Ultra immunostainer with a prediluted 
ready-to-use rabbit monoclonal primary 
antibody to PD-L1 (clone SP263, 
Ventana Medical Systems, Illkirch 
Cedex, France). Heat epitope retrieval 
as provided by the immunostainer was 
done in a TRIS based buffer supplied by 
the manufacturer (CC1 cell conditioning 
solution, Ventana Medical Systems, 
Illkirch Cedex, France) at pH 7.5 for 64 
minutes. The antibody was incubated at 
36° Celsius for 16 minutes. The 
enzymatic reactivity was visualized with 
3-3 diaminobenzidine (OptiView DAB 
IHC Detection Kit, Ventana, Illkirch 
Cedex, France, incubation time 8 
minutes). A human tonsil served as 
external positive control. For negative 
controls serial sections of the same 
specimens were used, omitting the 
primary antibody from the staining 
protocol and substituting it by a 
commercially available nonimmune IgG 
serum (DAKO). The 
immunohistochemical slides were 
evaluated and interpreted by the author 
(H.B.) without knowledge of the clinical 
data in a blinded manner. Necrotic 
tissue areas were not considered in the 
interpretation of immunostaining. 
Immunoreactivity was scored 
corresponding to the intensity and 
membranous pattern of the positive 
controls. To assess up-regulation and 
overexpression, sections were scored 
semi quantitatively as follows: score 0/1, 
0-5% immunoreactive cells; score 2+, 
>5 to 50% immunoreactive cells; score 
3+, >50% immunoreactive cells. The 
slides were screened at low power for 
any staining; higher magnification (x100) 
was used to determine 
immunohistochemical scores. This study 
investigated the epithelial expression of 
PD-L1 in the described epithelia; 
however, tumor- infiltrating immune cells 
were scored using the same criteria as 
in neoplastic epithelial tissues. 
The patterns of invasion in SCC were 
scored as pushing or diffuse. A cohesive 
growth with well delineated borders, 
sometimes finger-like tumor nests and 
well demarcation at the tumor-stroma-
interface was considered as pushing. 
Dissociative growth in small groups or 
single cells (“spray-like”) was defined as 
a diffuse pattern.12,18 To avoid statistical 
cohorts containing a few cases only 
mixed patterns of infiltration SCC were 
included into the cases defined as 
diffusely infiltrative.  
Statistical analysis was carried out using 
GraphPad Prism software (version 4.0, 
San Diego, CA). The chi-square test 
was used to analyse the 
immunoexpression scores of PD-L1. In 
SCC, scores of epithelial cells and 
tumor-infiltrating immune cells were 
compared by Pearson´s correlation.  
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Statistical significance was accepted at 
the p<0.05 level. 
Results  
Scores in the different diagnostic groups 
are shown in Table 1. If present, PD-L1 
immunostaining was noted in 
membranous and frequently associated 
cytoplasmic patterns (Figure 3).  
 
Table 1. Immunohistochemical expression of PD-L1 in normal and neoplastic 
squamous epithelia of the vulva. 
Diagnosis  PD-L1 IHS  
 0/1+ 2+ 3+ 
    
NE (n=20) 20 0 0 
uVIN (n=23) 20 3 0 
dVIN (n=21) 19 2  
SCC (n=35) 13 16 6 
    
SCC pushing pattern of invasion (n=27) 13 14 0 
SCC diffuse pattern of invasion (n=8) 0 2 6 
 
IHS, immunohistochemical score; n, number of cases; NE, normal vulvar squamous epithelia; uVIN, high-
grade vulvar intraepithelial neoplasia- usual type; dVIN, differentiated vulvar intraepithelial neoplasia; 
SCC, invasive squamous cell carcinoma of the vulva 
 
Figure 3. Membranous immunostaining for PD-L1 in a squamous cell carcinoma, 
diffusely infiltrating type (score 3+, x400). 
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In NE as well as VIN cases 
immunoscores were low (score 0/1, 
n=59; score 2+, n=5, in VINs only, 
Figures 4 and 5).There was no 
statistically significant difference 
between these cohorts (p=0.265, chi-
square test). Staining was most 
frequently localized to the basal and 
parabasal compartments of these 
epithelia, with rare reactivities of single 
cells in the upper epithelial levels.  
 
 
Figure 4. The case of dVIN shown in Fig. 1 with rare cells reactive for PD-L1, 
scored as group 0/1. Immunostaining is seen in subepithelial immune/stromal 
cells sometimes (x100). 
SCC PD-L1 expression was mainly 
localized to the tumor invasive front but 
could be observed in upper epithelial 
layers and central tumor regions in 
score 2+ and 3+ cases, respectively, 
too. (Figures 5 and 6) The latter staining 
was characteristic for the mixed pattern 
of infiltration tumors, too, which were 
included into the diffuse category. There 
was a statistically significant increase of 
immunoscores (score 0/1+, n=13; score 
2+, n=16; score 3+, n=6) in this cohort 
compared to the above described 
groups of NE and VINs (p<0.0001, chi-
square test).  
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Figure 5. A case of uVIN, PD-L1 score group 0/1. (x100). 
 
Figure 6. A squamous cell carcinoma showing a pushing type of infiltration. Rare 
epithelial immunostaining for PD-L1 is limited to cell layers at the infiltrative 
margin. Frequent PD-L1 reactivity is present in tumor-infiltrating immune cells, 
too (x100). 
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A pushing pattern of invasion was 
recorded in 27 cases of SCC. (Figure 6) 
In contrast, eight cases of SCC 
displayed a diffuse manner of invasion 
into the stroma with dissociative cell 
spread. (Figure 7) PD-L1 immunoscores 
were correlated with invasive patterns. 
They were lower in cases characterized 
by pushing growth (scores 0/1+, n=13; 
score 2+, n=14; score 3+, n=0), and 
increased in diffusely infiltrating tumors 
(score 0/1+, n=0; score 2+, n=2; score 
3+, n=6). These differences were 
statistically significant (p<0.0001, chi-
square test). Comparing VIN lesions 
with SCC of pushing type infiltration a 
strong statistical significance was 
calculated for an overexpression in the 
latter cohort (p=0.0009, chi-square test).  
 
 
Figure 7. A diffusely infiltrative squamous cell carcinoma, tumor cells are noted in 
small groups, corresponding to a spray-like pattern scored as 3+ on PD-L1 
immunostain (x400). 
PD-L1 stained tumor infiltrating immune 
cells were noted in different scores in 
VIN cases; since epithelial scores were 
generally low in these lesions, no 
correlation for epithelial and tumor-
infiltrating immune cell scores was 
calculated . In the SCC cohort scores 
were frequently low (score 0/1+, n=22; 
score 2, n=9; score3, n=4). There was 
no correlation between epithelial and 
tumor-infiltrating cell scores in the group 
of SCCs (Pearson correlation, 
p=0.8943, Pearson r=0.0233). 
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Discussion 
PD-L1 which is expressed in many 
cancer cells, prevents tumor death by 
blocking T cell activity and has been 
shown a predictive biomarker in cancer 
immunotherapy.8,19 This study assessed 
the PD-L1 immunoreactivity in vulvar 
epithelial neoplasia by evaluating 
squamous intraepithelial neoplasia (VIN 
of different subtypes) in comparison to 
early invasive non-HPV associated 
keratinizing subtype SCC of FIGO stage 
I and different patterns of invasion of 
SCC. Up-regulation of PD-L1 was 
observed between VIN and SCC as well 
as for a diffuse pattern of stromal 
invasion in the latter.  
The pattern of invasion has been shown 
an important factor in the aggressivity of 
female lower genital tract SCC. For 
cervical SCC, Horn et al. defined a 
closed pattern of infiltration as cohesive 
growth with well-delineated pushing 
borders, a finger-like pattern of tumor 
growth in solid cords and trabecles, and 
a highly dissociative growth in small 
groups or single cells as a spray-like 
pattern with the highest degree of tumor 
cell dissociation.18 They noted that the 
spray-like pattern was associated with 
advanced tumor stages, increased rate 
of recurrence and a reduced overall 
survival. For the purpose of the study at 
hand with its limited number of FIGO 
stage I SCC the latter pattern was 
defined as diffuse pattern. Others 
reported for vulvar cancers that tumors 
with an infiltrative pattern of invasion 
and fibromyxoid stroma were associated 
with worse outcomes and the 
development of epithelial-mesenchymal 
transition than tumors with pushing or 
nested patterns.12 In the study by 
Holthoff et al. an infiltrative pattern of 
invasion was defined as cords or 
individual tumor cells infiltrating the 
surrounding stroma in a spray-like 
patter.12 Generally, the pattern of 
invasion in cancers in its relation to PD-
L1 expression is studied rarely. It has 
been shown that PD-L1 was significantly 
overexpressed in the budding areas in 
patients with localized colon cancer and 
that its levels correlated with a 
mesenchymal transition profile. The 
authors pointed to the importance of 
including budding areas among the 
samples used for biomarker 
evaluation.20 Tumor budding 
corresponds with the category of diffuse 
infiltration in this study morphologically. 
To the best of the author´s knowledge 
the study at hand is the first one to 
describe PD-L1 immunoexpression in 
this setting in vulvar SCC.   
The group of SCC in this study was 
HPV-negative. However, the VIN lesions 
covered both HPV dependent uVIN as 
well as HPV independent dVIN. There 
was no significant difference of PD-L1 
expression between these two cohorts. 
Interestingly, Mezache et al reported 
that about 95% of their cervical 
intraepithelial lesions (CIN), which are 
known to be HPV dependent, expressed 
PD-L1 and concluded that PD-L1 is a 
solid biomarker of productive HPV 
infection of the cervix.21 Others noted 
that PD-L1 overexpression is detectable 
in a substantial proportion of vulvar 
carcinomas in all stages and is 
independent of HPV.7,8 Chinn et al. 
found that the majority of intraepithelial 
lesions of the cervix and vulva were 
entirely negative for PD-L1, which is 
largely in agreement with the data 
reported in this study with respect to 
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dVIN and uVIN.11 They showed no 
difference of PD-L1 expression in dVIN 
associated versus HPV-associated 
vulvar squamous cell carcinomas. 
However, there are controversies 
concerning the use of different PD-L1 
antibodies in different studies, and the 
use of specific and validated antibodies 
is mandatory.11,22 Other reasons for 
differences include interpretative 
variability and antibody titration.11 Using 
a different scoring system Hecking et al. 
found membranous PD-L1 expression in 
a minority of their HPV-negative vulvar 
cancers.23 They described a 
geographical correlation of PD-L1 with 
immunocyte-rich regions of cancer 
islets, which was an independent 
prognostic factor for poor outcome. 
However, an analysis of the pattern of 
infiltration was not done there. The 
study at hand focused on epithelial 
expression of PD-L1. Thus, the scoring 
method differs from other studies using 
for instance the combined positive score 
(CPS) which includes tumor infiltrating 
immune cells in the final score 
complicating the direct comparison 
between different papers.11 
A genetic basis for PD-L1 expression in 
SCC of the vulva has been described 
recently. Recurrent copy number gain of 
the genes encoding the PD-1 ligands 
provided evidence for PD-L1 expression 
in a subset of cervical and vulvar 
cancers.9 These data were interpreted 
as a hint towards a class of patients that 
are rational candidates for therapies 
targeting PD-1. Indeed, pembrolizumab, 
a humanized monoclonal antibody 
against PD-1, has been shown a safe 
and effective chemotherapeutic agent to 
treat recurrent vulvar carcinoma 
cases.10 Xing et al. reported on different 
mutational profiles and PD-L1 
expression in some cases of primary 
and metastatic vulvar SCC and 
emphasized the importance of PD-L1 
expression in different tumor locations to 
avoid false negative information 
provided for immunotherapy.6 
The clinical response to therapies 
targeting the PD-1/PD-L1 pathway is 
impressive in some patients; however, 
this approach has not proved uniformly 
effective.11 As discussed above there 
are different possible multifactorial 
reasons for this including technical 
issues, immunohistochemical antibody 
variability, intratumoral heterogeneity, as 
well as complex phenomena in the 
immune response to cancer.11 
Clinicopathologic and histological 
features associated with PD-L1 
expression are still poorly described. 
One study concluded that there was no 
association of PD-L1 expression to 
clinicopathologic parameters like 
histologic tumor type, tumor and nodal 
stage, grading, and overall survival in 
vulvar carcinomas; there was no 
reference to the pattern of invasion.8 
Chinn et al. noted that PD-L1 
expression is common, but typically only 
focal among vulvar SCC with and 
without HPV association, and suggested 
that anti-PD-1/PD-l1 inhibitors may work 
only in select cases.11 Including patterns 
of infiltration which are known factors of 
aggressive tumor behavior and 
epithelial-mesenchymal transition may 
help to discuss appropriate therapies on 
the background of PD-L1 expression.  
The pattern of invasion in vulvar SCC 
may be characterized by 
immunohistochemical features. Holthoff 
et al. investigated a cohort of these 
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cancers by similar criteria as used in this 
study, namely pushing versus infiltrative 
(“spray-like”).12 They showed that an 
infiltrative pattern is more likely to exhibit 
features reflective of an epithelial-
mesenchymal transition. Nuclear beta-
catenin and presence of vimentin were 
significantly more likely to occur in 
tumors with an infiltrative pattern of 
invasion or a fibromyxoid stromal 
response, loss of E-cadherin was just 
associated significantly with an 
infiltrative pattern. They concluded that 
loss of cell-to-cell junction may also be 
an important factor in the development 
of the spray-like appearance of the 
infiltrative invasive pattern. Thus, PD-L1 
overexpression in diffuse type invasive 
vulvar SCC shown in this study may be 
compatible with other molecular features 
of tumor aggressivity, with relevance to 
the tumor immunology. 
PD-L1 immunoexpression needs to be 
scored for membranous reactivity.11 
However, additional cytoplasmic 
staining was observed in many cases in 
this study as well as by others.24  
Although cytoplasmic staining is not a 
specific pattern of reactivity, this may 
indicate a constitutive overexpression of 
PD-L1 by tumor cells, consistent with 
the recurrent copy number gain of the 
genes encoding the PD-1 ligands in 
some of these cancers.9,24 
This study is limited by a relatively small 
number of cases. Based on the low 
stage cancers investigated it does not 
answer questions on tumor recurrence 
and survival. Since there is an emphasis 
on morphological features of invasion of 
the epithelial neoplastic cells the PD-L1 
status of tumor infiltrating immune cells 
was not evaluated in depth. However, 
there was no correlation of 
immunoscores between epithelial and 
tumor-infiltrating immune cells in SCC. 
Further studies on larger case cohorts 
including PD-L1 staining and 
characterisation of immune cells, high 
stage cancers and data on recurrence/ 
survival of patients are necessary to 
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